Release no 24/2010
Copenhagen and Oslo, 7th July, 2010
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
announced the new Company address in Copenhagen.
As per July 1st 2010 Affitech A/S address is c/o COBIS, Ole Maaløes Vej 3, DK
2200 Copenhagen N.
COBIS is the first dedicated biotechnology Science Park in the Copenhagen
region. It opened in November 2009 and is centrally located at Copenhagen
university campus close to Copenhagen's leading hospital Rigshospitalet.
--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
Randi Krogsgaard, Corporate Communications |
Tel # +45 2320 1001 |
--------------------------------------------------------------------------------
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.